Stepwise options for preparing therapeutic plasma proteins from domestic plasma in low‐ and middle‐income countries

Abstract

AbstractIndustrial plasma fractionation, a complex and highly regulated technology, remains largely inaccessible to many low‐ and middle‐income countries (LMICs). This, combined with the limited availability and high cost of plasma‐derived medicinal products (PDMPs), creates deficiency of access to adequate treatment for patients in resource‐limited countries, and leads to their suffering. Meanwhile, an increasing number of LMICs produce surplus plasma, as a by‐product of red blood cell preparation from whole blood, that is discarded because of the lack of suitability for fractionation. This article reviews pragmatic technological options for processing plasma collected from LMICs into therapies and supports a realistic stepwise approach aligned with recent World Health Organization guidance and initiatives launched by the Working Party for Global Blood Safety of the International Society of Blood Transfusion. When industrial options based on contract or toll plasma fractionation programme and, even more, domestic fractionation facilities require larger volumes of quality plasma than is produced, alternative methods should be considered. In‐bag minipool or small‐scale production procedures implementable in blood establishments or national service centres are the only realistic options available to gradually reduce plasma wastage, provide safer treatments for patients currently treated with non‐pathogen‐reduced blood products and concurrently improve Good Manufacturing Practice (GMP) levels with minimum capital investment. As a next step, when the available volume of quality‐assured plasma reaches the necessary thresholds, LMICs could consider engaging with an established fractionator in a fractionation agreement or a contract in support of a domestic fractionation facility to improve the domestic PDMP supply and patients' treatment.